Literature DB >> 2784039

Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine.

J L Tate.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2784039     DOI： 10.1176/ajp.146.3.399b

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  16 in total

Review 1.  Depression in Parkinson's disease.

Authors:  Theresa A Zesiewicz; Robert A Hauser
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

2.  Neurotransmitters in CSF of idiopathic adult-onset dystonia: reduced 5-HIAA levels as evidence of impaired serotonergic metabolism.

Authors:  M Naumann; M Götz; K Reiners; K W Lange; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol.

Authors:  J Fang; G B Baker; P H Silverstone; R T Coutts
Journal:  Cell Mol Neurobiol       Date:  1997-04       Impact factor: 5.046

Review 4.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 5.  Clinical pharmacokinetics of fluoxetine.

Authors:  A C Altamura; A R Moro; M Percudani
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

6.  Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area.

Authors:  S Prisco; E Esposito
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

Review 7.  Clinical pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  J van Harten
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

Review 8.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

Review 9.  Management of the negative symptoms of schizophrenia: new treatment options.

Authors:  Hans-Jürgen Möller
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia.

Authors:  D C Goff; K K Midha; O Sarid-Segal; J W Hubbard; E Amico
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.